<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Cryptosporidiosis: Treatment and prevention</title><link href="/z/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/z/d/css/icofont.min.css" rel="stylesheet"/><link href="/z/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/z/d/css/animate.css" rel="stylesheet"/><link href="/z/d/css/owl.carousel.css" rel="stylesheet"/><link href="/z/d/css/magnific-popup.css" rel="stylesheet"/><link href="/z/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/z/d/css/style.css" rel="stylesheet"/><link href="/z/d/css/rtl_edited.css" rel="stylesheet"/><link href="/z/d/css/responsive.css" rel="stylesheet"/><link href="https:///uptodate_assets/main.css" rel="stylesheet"/>
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>
<meta content="" name="description"/>
<link href="/z/d/img/favicon.png" rel="icon" type="image/png">
</link></head>
<body>
<!-- Start Main Menu Area -->
<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>
<section class="teacher-area ptb-10">
<div class="container">
</div>
<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Cryptosporidiosis: Treatment and prevention</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Cryptosporidiosis: Treatment and prevention</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Authors:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Karin Leder, MBBS, FRACP, PhD, MPH, DTMH</a></dd><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Peter F Weller, MD, MACP</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Edward T Ryan, MD, DTMH</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Milana Bogorodskaya, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Aug 05, 2022.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H13466474"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span><em>Cryptosporidium</em> is an intracellular protozoan parasite that is associated with self-limited diarrhea in immunocompetent hosts and severe debilitating diarrhea with weight loss and malabsorption in immunocompromised patients (eg, patients with acquired immunodeficiency syndrome [AIDS]). The approach to treatment for patients with cryptosporidiosis depends upon the immune status of the host as well as the severity of symptoms. There are different species of cryptosporidia that infect humans with the most common being <em>Cryptosporidium hominis</em>, and <em>Cryptosporidium parvum</em>. The approach to treatment and the expected response to therapy among the different species do not differ. (See  <a class="medical medical_review" href="/z/d/html/5733.html" rel="external">"Cryptosporidiosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Microbiology'</a>.)</p><p>This topic will address the treatment and prevention of cryptosporidiosis in immunocompetent patients, patients with human immunodeficiency virus (HIV), and other immunocompromised patients. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of cryptosporidiosis are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/5733.html" rel="external">"Cryptosporidiosis: Epidemiology, clinical manifestations, and diagnosis"</a>.)</p><p class="headingAnchor" id="H622119034"><span class="h1">SUPPORTIVE THERAPY</span><span class="headingEndMark"> — </span>Supportive therapy is the mainstay of treatment in all patients with cryptosporidiosis. As with all diarrheal illnesses, ensuring adequate volume status is the main goal of supportive therapy and is primarily done through oral volume repletion and antidiarrheal agents, if needed. </p><p>Repletion of electrolyte losses by either oral or intravenous routes is important in patients who experience significant volume loss associated with severe diarrhea. Volume loss of &gt;10 liters per day has been reported in patients with cryptosporidiosis who have "cholera-like" diarrhea, which can be life-threatening without aggressive repletion [<a href="#rid1">1</a>].</p><p>Additional supportive therapy with antidiarrheal agents can be used in any patient with cryptosporidiosis who cannot keep up with their fluid losses because of excessive volume of watery stools per day. <a class="drug drug_general" data-topicid="9571" href="/z/d/drug information/9571.html" rel="external">Loperamide</a> is often used for control of diarrhea. However, <a class="drug drug_general" data-topicid="9721" href="/z/d/drug information/9721.html" rel="external">tincture of opium</a> may be more effective than loperamide [<a href="#rid1">1</a>]. </p><p>In patients with chronic symptoms (&gt;4 to 6 weeks) associated with significant weight loss leading to cachexia, total <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a> should also be considered. Additional discussions of fluid management are found elsewhere. (See  <a class="medical medical_review" href="/z/d/html/6129.html" rel="external">"Oral rehydration therapy"</a> and  <a class="medical medical_review" href="/z/d/html/2704.html" rel="external">"Cholera: Epidemiology, clinical features, and diagnosis"</a>.)</p><p class="headingAnchor" id="H2996206669"><span class="h1">OTHER MANAGEMENT ISSUES</span></p><p class="headingAnchor" id="H1384290981"><span class="h2">Patients with advanced HIV</span><span class="headingEndMark"> — </span>For patients with HIV, we recommend antiretroviral therapy (ART) to restore immune function, and in some cases, antimicrobial therapy against cryptosporidiosis while awaiting CD4 cell recovery [<a href="#rid2">2</a>]. These interventions should be administered in addition to supportive care. (See <a class="local">'Supportive therapy'</a> above.)</p><p>Selection of an ART regimen is discussed elsewhere. (See  <a class="medical medical_review" href="/z/d/html/3773.html" rel="external">"Selecting antiretroviral regimens for treatment-naïve persons with HIV-1: General approach"</a>.)</p><p>Patients with HIV on ART with viral suppression and presumed restoration of immune function can be managed similar to those without HIV infection. (See <a class="local">'Immunocompetent hosts'</a> below.)</p><p class="headingAnchor" id="H1661280217"><span class="h3">Impact of antiretroviral therapy</span><span class="headingEndMark"> — </span>ART should be initiated in all patients with HIV as soon as possible [<a href="#rid1">1</a>]. Those diagnosed with cryptosporidiosis typically are not on ART and have a low CD4 cell count. </p><p>Immune restoration with ART is critical to symptom eradication and prognosis. Retrospective analyses and case series have found that immune restoration with a CD4 count greater than 100 cells/microL is associated with resolution of symptoms; it is unclear whether organisms are completely eliminated [<a href="#rid3">3-5</a>]. </p><p>In patients with cryptosporidiosis and HIV infection, the prognosis without immune restoration is generally poor. In one study that followed 128 patients with HIV with cryptosporidiosis, more than half developed chronic disease, and approximately 10 percent developed fulminant disease (passage of more than 21 stools per day from the time of presentation) [<a href="#rid6">6</a>]. The mean survival was 20 weeks for those with chronic disease, but only five weeks for those with fulminant infection. Fulminant disease only occurred in patients with a CD4 count less than 50 cells/microL, therefore, it was difficult to assess the relative contribution of <em>Cryptosporidium </em>to mortality. However, in other reports, cryptosporidiosis appears to be independently associated with decreased survival [<a href="#rid1">1,7-9</a>]. </p><p class="headingAnchor" id="H3817198164"><span class="h3">Antimicrobial therapy</span><span class="headingEndMark"> — </span>Antimicrobial therapy is reserved for patients with severe symptoms or those with persistent symptoms that did not resolve with initiation of ART.</p><p class="headingAnchor" id="H1191565865"><span class="h4">Persistent nonsevere symptoms</span><span class="headingEndMark"> — </span>For patients with HIV who have persistent symptoms despite ART initiation, we suggest antimicrobial therapy [<a href="#rid1">1</a>]. Although data are mixed, it is possible that some patients may benefit from it. We prefer monotherapy with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> for all patients ≥1 year of age [<a href="#rid10">10-15</a>]. Once the diarrhea has resolved, treatment can be discontinued. For patients who do not respond to initial monotherapy, a trial of combination therapy is reasonable [<a href="#rid16">16-20</a>]. (See <a class="local">'Severe symptoms or treatment failure'</a> below.) </p><p>The dose of <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> for adults and children &gt;12 years is 500 to 1000 mg twice daily; the dose for children 1 to 3 years is 100 mg twice daily and for children 4 to 11 years 200 mg twice daily. We give nitazoxanide for two to eight weeks depending on response [<a href="#rid1">1,11</a>]. In general, nitazoxanide is well tolerated; most side effects are gastrointestinal (eg, abdominal cramping) and are not severe. This agent is the only therapy approved by the US Food and Drug Administration for the treatment of cryptosporidiosis.</p><p><a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">Paromomycin</a> (500 mg three times daily for one week; pediatric dose 25 to 35 mg/kg/day) is generally used as an alternative agent if <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> cannot be used. </p><p>The clinical benefit of antimicrobial therapy in patients with HIV is uncertain as data are limited and mixed; it is less effective than in immunocompetent hosts. Most data are with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a>. An early compassionate use trial that included 365 individuals with HIV and cryptosporidiosis found that nitazoxanide (500 to 1500 mg twice daily) given for a median of 62 days (range 1 to 1528) resulted in a sustained clinical response in 59 percent of patients while on treatment [<a href="#rid21">21</a>]. However, other studies have found that nitazoxanide by itself is not likely to be effective [<a href="#rid10">10,12,22,23</a>]. In a meta-analysis that included seven trials and 169 immunosuppressed participants (130 adults with AIDS), nitazoxanide did not lead to significant evidence of oocyst clearance among participants with HIV (relative risk 0.71, 95% CI 0.36 to -1.37), and did not have a clear impact on duration and frequency of diarrhea [<a href="#rid10">10</a>]. Similarly, a subsequent randomized trial in 52 children with HIV in Zambia, nitazoxanide (used both at a high dose [200 mg twice daily for children aged 1 to 3 years; 400 mg twice daily for children aged 4 to 11 years] and for a prolonged [28 days] course) had no clear clinical or parasitologic benefits compared with placebo [<a href="#rid23">23</a>].</p><p><a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">Paromomycin</a> monotherapy also has little effect on symptoms and oocyst shedding in patients with HIV [<a href="#rid24">24,25</a>], and in the meta-analysis described above, paromomycin did not have any effect on the duration or frequency of diarrheal symptoms [<a href="#rid10">10</a>]. <a class="drug drug_general" data-topicid="10202" href="/z/d/drug information/10202.html" rel="external">Rifaximin</a> and <a class="drug drug_general" data-topicid="9863" href="/z/d/drug information/9863.html" rel="external">rifabutin</a> have shown some efficacy although data are limited [<a href="#rid26">26-31</a>]. There are also reports of <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> alone improving clinical outcomes in patients with HIV with cryptosporidiosis [<a href="#rid32">32</a>], but responses have been variable. </p><p>Other therapies that have been tried in patients with HIV include <a class="drug drug_general" data-topicid="10092" href="/z/d/drug information/10092.html" rel="external">spiramycin</a>, <a class="drug drug_general" data-topicid="9273" href="/z/d/drug information/9273.html" rel="external">clarithromycin</a>, <a class="drug drug_general" data-topicid="9714" href="/z/d/drug information/9714.html" rel="external">octreotide</a>, diclazuril and letrazuril, <a class="drug drug_general" data-topicid="8957" href="/z/d/drug information/8957.html" rel="external">atovaquone</a>, <a class="drug drug_general" data-topicid="107872" href="/z/d/drug information/107872.html" rel="external">clofazimine</a>, and hyperimmune bovine colostrum, all of which have been associated with minimal to no symptomatic benefits, and without sustained parasitologic cure [<a href="#rid33">33-36</a>]. Cryptosporidial proteases, which are involved in the host-cell interaction, have been identified and could lead to new therapeutic approaches using specific parasite protease inhibitors in immunocompromised persons [<a href="#rid27">27,37</a>]. </p><p class="headingAnchor" id="H1606220994"><span class="h4">Severe symptoms or treatment failure</span><span class="headingEndMark"> — </span>For those with severe acute symptoms causing significant morbidity and dehydration (stool volumes of &gt;10 L per day) or persistent symptoms (ie, diarrhea after two to eight weeks of monotherapy), we suggest combination antimicrobial therapy in addition to supportive therapy and immune restoration with ART. We typically use the combination of <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> or <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> plus <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> (500 mg once daily). The duration of treatment depends upon the patient's response to therapy and immunologic recovery. In refractory cases, therapy may be extended over months with the hope of benefit; if symptoms resolve, therapy may be discontinued. </p><p>Although controlled, large-scale trials are lacking, the use of combination therapy is supported by findings from small case series [<a href="#rid16">16-20</a>]. As an example, in a case series of 11 patients with AIDS, <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> plus <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> resulted in a marked reduction in oocyst excretion and a modest reduction in stool frequency by 12 weeks [<a href="#rid16">16</a>]. Good results were also seen when this combination was used to treat a patient with extraintestinal cryptosporidiosis.</p><p class="headingAnchor" id="H1447886561"><span class="h2">Other immunocompromised hosts</span><span class="headingEndMark"> — </span>Patients with immunocompromising conditions other than HIV (eg, those who have undergone solid organ transplant) have also been reported to have refractory cryptosporidiosis [<a href="#rid38">38,39</a>]. For such patients, we attempt to reduce the dose of immunosuppressive therapy, if possible, and also suggest antimicrobial therapy. This is consistent with the American Society of Transplant Infectious Diseases, which recommends antimicrobial therapy of cryptosporidiosis in patients with solid organ transplant [<a href="#rid40">40</a>]. We typically use <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> monotherapy. In patients with more severe disease, combination therapy is a reasonable alternative. </p><p><a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">Nitazoxanide</a> (500 to 1000 mg twice daily for adults and children ≥12 years, 100 mg twice daily for children 1 to 3 years, and 200 mg twice daily for children 4 to 11 years) is administered for at least two weeks; the ultimate duration should be guided by the clinical response (reduction in volume of diarrhea). </p><p>Potential combination regimens include <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> or <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> in combination with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a>. However, caution with toxicity monitoring is warranted because macrolide antibiotics in combination with calcineurin inhibitors and mammalian target of rapamycin inhibitors can significantly prolong the QT interval. </p><p>Data informing the optimal antimicrobial therapy of cryptosporidiosis in immunocompromised patients are limited but suggest some benefit.</p><p>The use of <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> treatment for &gt;14 days was supported in a case series that evaluated six children who developed cryptosporidiosis following solid organ transplantation [<a href="#rid39">39</a>]. All the patients eventually recovered; however, the two patients who received a short course (five days) of therapy had an initial recurrence of symptoms when treatment was discontinued. </p><p>Treatment with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> and <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> for four to six weeks resulted in clinical as well as a parasitologic cures in small case series of kidney and hematopoietic cell transplant patients [<a href="#rid17">17,20</a>].</p><p class="headingAnchor" id="H1112020112"><span class="h2">Treatment of biliary tract disease</span><span class="headingEndMark"> — </span>Biliary tract involvement is an uncommon complication of cryptosporidiosis in patients with underlying immunosuppression [<a href="#rid41">41,42</a>]. In addition to antimicrobial therapy, antiretroviral therapy in patients with HIV and reduction of immunosuppressive therapy in organ transplant patients, treatment of biliary tract disease with cryptosporidiosis may require specific interventions and is discussed in detail elsewhere. (See  <a class="medical medical_review" href="/z/d/html/667.html" rel="external">"AIDS cholangiopathy"</a>.) </p><p class="headingAnchor" id="H1314611105"><span class="h2">Immunocompetent hosts</span><span class="headingEndMark"> — </span>Immunologically healthy patients usually have a spontaneous recovery within a few days to weeks and a parasitologic cure within a few weeks to months without requiring any specific therapy. </p><p class="headingAnchor" id="H3465294592"><span class="h3">Mild symptoms</span><span class="headingEndMark"> — </span>Most patients with cryptosporidiosis have mild to moderate symptoms and are able to keep up with their fluid losses without the need for additional therapies during the limited time that symptoms are usually present. However, if symptoms are persistent (&gt;2 weeks) antibiotic therapy may be warranted. (See <a class="local">'Antimicrobial therapy'</a> above.)</p><p class="headingAnchor" id="H2942865019"><span class="h3">Severe symptoms</span><span class="headingEndMark"> — </span>It is uncommon for cryptosporidiosis to present with sufficiently severe symptoms that antimicrobial treatment of immunocompetent patients is warranted. However, patients may occasionally have an excessive number of watery stools or have symptoms for a prolonged period of time that may interfere with their quality of life or ability to maintain adequate hydration.</p><p>For those with severe acute symptoms causing significant morbidity and dehydration (stool volumes of &gt;10 L per day), or persistent symptoms (ie, diarrhea lasting &gt;2 weeks), we recommend antimicrobial therapy in addition to supportive care. Antimicrobial therapy consists of <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> for three days; the dose of nitazoxanide depends upon the patient's age [<a href="#rid11">11-13</a>]: </p><p class="bulletIndent2"><span class="glyph">•</span>For children 1 to 3 years: 100 mg twice daily </p><p class="bulletIndent2"><span class="glyph">•</span>For children 4 to 11 years: 200 mg twice daily </p><p class="bulletIndent2"><span class="glyph">•</span>For patients 12 years and older: 500 mg twice daily</p><p></p><p>If <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> is not available or not tolerated, <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> can be used (500 mg three times daily for one week; pediatric dose 25 to 35 mg/kg/day). Paromomycin is a nonabsorbable aminoglycoside indicated for the treatment of intestinal amebiasis, but it is not specifically approved for cryptosporidiosis, and data are conflicting [<a href="#rid10">10,15,24,25</a>]. </p><p>Several randomized trials in both immunocompetent adults and children have shown improvement of diarrhea as well as increased eradication of oocysts with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> [<a href="#rid12">12,13,15</a>]. As an example, in a randomized trial of 100 adults and children with limited follow-up of 7 to 10 days, nitazoxanide increased the likelihood of resolution of diarrhea within three to four days (88 versus 38 percent with placebo) and elimination of oocyst shedding (75 versus 20 percent) [<a href="#rid13">13</a>].</p><p><a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">Nitazoxanide</a> also has superior efficacy compared with <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> [<a href="#rid43">43</a>]. In a trial of 90 children aged 6 months to 10 years with <em>Cryptosporidium</em> spp infection and diarrhea for more than 15 days, complete clinical and laboratory cure occurred in 87 percent of those who received three days of nitazoxanide compared with 69 percent who received paromomycin. </p><p class="headingAnchor" id="H1472781855"><span class="h3">Response to treatment</span><span class="headingEndMark"> — </span>A reduction in the overall volume of daily stool and ultimate resolution of diarrhea is the goal of therapy. If symptoms persist with no significant reduction in stool, it is prudent to recheck stools for oocysts to determine if infection is still present. If infection persists, <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> or combination therapy with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> and paromomycin can be given.</p><p class="headingAnchor" id="H3724314685"><span class="h3">Persistent nonspecific symptoms</span><span class="headingEndMark"> — </span>There is no role for antimicrobial therapy for late occurring extraintestinal symptoms (eg, joint pain, eye pain, headache) although symptoms have been reported to be present up to two years after infection [<a href="#rid44">44</a>]. (See  <a class="medical medical_review" href="/z/d/html/5733.html" rel="external">"Cryptosporidiosis: Epidemiology, clinical manifestations, and diagnosis", section on 'Long-term sequelae'</a>.)</p><p class="headingAnchor" id="H13465874"><span class="h1">PREVENTION</span></p><p class="headingAnchor" id="H3654701171"><span class="h2">Counseling for infected patients</span><span class="headingEndMark"> — </span>People with cryptosporidial diarrhea should be counseled on strategies to minimize the risk of transmission to others. These include practicing good hygiene and hand washing. They should also avoid swimming in public pools for two weeks after the diarrhea has resolved, as this is key to controlling cryptosporidiosis outbreaks associated with aquatic facilities [<a href="#rid45">45,46</a>]. </p><p>Asymptomatic close contacts do not routinely require any specific investigation or therapy, but these individuals should be aware that they may be excreting oocysts and therefore should practice frequent handwashing.</p><p class="headingAnchor" id="H1723019432"><span class="h2">Preventing infection</span><span class="headingEndMark"> — </span>Good hygiene (eg, handwashing and proper disposal of contaminated material) are important in preventing infection. Protection of water sources and water filtration are also key [<a href="#rid45">45</a>]. Prevention of outbreaks of cryptosporidiosis requires surveillance and monitoring of drinking water supplies. Oocysts are resistant to most standard purification techniques, including chlorination. However, oocysts can be eliminated with freezing, boiling, and/or by filtration or using high concentrations of ammonia or formalin [<a href="#rid34">34</a>]. </p><p>Immunocompromised patients who are at high risk for severe infection should limit their exposure to cryptosporidia by minimizing oral exposure to water from lakes, streams, and public swimming pools [<a href="#rid46">46</a>]. Boiling or filtering water may also decrease the risk of infection in immunosuppressed patients; however, the impact of low concentrations of oocysts in drinking water on human illness is not adequately understood, and this approach is not universally recommended. </p><p>For patients with HIV, the best prophylaxis is early initiation of antiretroviral therapy. Antimicrobial prophylaxis<em> for Cryptosporidium</em> is not routinely recommended [<a href="#rid1">1</a>]. </p><p>No vaccine for cryptosporidiosis exists. While adults in highly endemic areas are partially immune to reinfection, clear understanding of the human protective immune response including mucosal, humoral, and intestinal immune responses to the parasite are lacking. Additionally, durability and persistence of immunity after resolution of infection are unknown, and uncertainty remains regarding the optimal antigens for inclusion should a vaccine be produced [<a href="#rid47">47,48</a>].</p><p class="headingAnchor" id="H1194575534"><span class="h1">SOCIETY GUIDELINE LINKS</span><span class="headingEndMark"> — </span>Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See  <a class="medical medical_society_guidelines" href="/z/d/html/109942.html" rel="external">"Society guideline links: Acute diarrhea in adults"</a> and  <a class="medical medical_society_guidelines" href="/z/d/html/111612.html" rel="external">"Society guideline links: Opportunistic infections in adults with HIV"</a>.)</p><p class="headingAnchor" id="H26989078"><span class="h1">INFORMATION FOR PATIENTS</span><span class="headingEndMark"> — </span>UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5<sup>th</sup> to 6<sup>th</sup> grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10<sup>th</sup> to 12<sup>th</sup> grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.</p><p>Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.) </p><p class="bulletIndent1"><span class="glyph">●</span>Basics topic (see  <a class="medical medical_basics" href="/z/d/html/83627.html" rel="external">"Patient education: Cryptosporidiosis (The Basics)"</a>)</p><p></p><p class="headingAnchor" id="H13466493"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Overview</strong> − <em>Cryptosporidium </em>is an intracellular protozoan parasite that is associated with self-limited diarrhea in immunocompetent hosts and severe debilitating diarrhea with weight loss and malabsorption in immunocompromised patients (eg, patients with AIDS). (See <a class="local">'Introduction'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Supportive therapy</strong> − Most patients are able to keep up with their fluid losses without the need for additional therapies. However, for patients who are unable to keep up with fluid losses, supportive care includes volume repletion, antimotility agents, and rarely, enteral or <a class="drug drug_general" data-topicid="10307" href="/z/d/drug information/10307.html" rel="external">parenteral nutrition</a>. (See <a class="local">'Supportive therapy'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompromised patients</strong> − For immunocompromised patients, the treatment approach depends on the severity of diarrhea and the underlying condition: </p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with advanced HIV </strong></p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients with advanced HIV and cryptosporidiosis, initiation of antiretroviral therapy (ART) is the primary intervention. Immune reconstitution has been associated with resolution of symptoms. (See <a class="local">'Impact of antiretroviral therapy'</a> above.) </p><p></p><p class="bulletIndent3"><span class="glyph">-</span>For patients who have persistent (nonsevere) symptoms despite ART (or while awaiting CD4 cell recovery), we suggest antimicrobial therapy with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Although it is of uncertain benefit, it may lead to clinical improvement in some patients. (See <a class="local">'Patients with advanced HIV'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Patients with other immunocompromising conditions</strong> − For patients with other immunocompromising conditions (eg, those who have undergone solid organ transplant), we reduce the dose of immunosuppressive therapy if possible. In addition, for patients with nonsevere diarrhea, we suggest antimicrobial therapy with <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). Nitazoxanide is given for at least two weeks. (See <a class="local">'Other immunocompromised hosts'</a> above.)</p><p></p><p class="bulletIndent2"><span class="glyph">•</span><strong>Severe diarrhea</strong> <strong>and/or refractory disease</strong> − For patients with advanced HIV and other immunocompromising conditions who have severe diarrhea (stool volume &gt;10 L per day) or have failed initial treatment, we suggest combination therapy rather than monotherapy (<a class="grade" href="https:///uptodate/show/grade_6" rel="external">Grade 2C</a>). <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">Nitazoxanide</a> or <a class="drug drug_general" data-topicid="9742" href="/z/d/drug information/9742.html" rel="external">paromomycin</a> used in combination with <a class="drug drug_general" data-topicid="9041" href="/z/d/drug information/9041.html" rel="external">azithromycin</a> may lead to improved clinical outcomes in certain immunocompromised hosts. (See <a class="local">'Severe symptoms or treatment failure'</a> above.) </p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Immunocompetent patients </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Immunocompetent patients usually have a spontaneous recovery within a few days to weeks and parasitologic cure within a few weeks to months without requiring any specific therapy. </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For immunocompetent patients who have severe acute symptoms or symptoms for greater than 14 days, we recommend <a class="drug drug_general" data-topicid="10105" href="/z/d/drug information/10105.html" rel="external">nitazoxanide</a> for three days, rather than supportive care alone (<a class="grade" href="https:///uptodate/show/grade_2" rel="external">Grade 1B</a>). Treatment with nitazoxanide leads to more rapid resolution of symptoms. (See <a class="local">'Immunocompetent hosts'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span><strong>Prevention </strong></p><p></p><p class="bulletIndent2"><span class="glyph">•</span>Good handwashing and proper disposal of contaminated material are the most important ways to prevent infection. In addition, people with cryptosporidial diarrhea should be advised to avoid swimming in public pools for two weeks after the diarrhea has resolved. (See <a class="local">'Prevention'</a> above.) </p><p></p><p class="bulletIndent2"><span class="glyph">•</span>For immunocompromised patients, antimicrobial prophylaxis for <em>Cryptosporidium</em> is not routinely administered. However, patients should minimize oral exposure to water from lakes, streams, public swimming pools, and water parks. (See <a class="local">'Prevention'</a> above.)</p><p></p></div><div class="headingAnchor" id="references"><ol id="reference"><li class="breakAll">Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on July 25, 2023).</li><li><a class="nounderline abstract_t">Sparks H, Nair G, Castellanos-Gonzalez A, White AC Jr. Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward. Curr Trop Med Rep 2015; 2:181.</a></li><li><a class="nounderline abstract_t">Carr A, Marriott D, Field A, et al. Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy. Lancet 1998; 351:256.</a></li><li><a class="nounderline abstract_t">Miao YM, Awad-El-Kariem FM, Franzen C, et al. Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy. J Acquir Immune Defic Syndr 2000; 25:124.</a></li><li><a class="nounderline abstract_t">Maggi P, Larocca AM, Quarto M, et al. Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1. Eur J Clin Microbiol Infect Dis 2000; 19:213.</a></li><li><a class="nounderline abstract_t">Blanshard C, Jackson AM, Shanson DC, et al. Cryptosporidiosis in HIV-seropositive patients. Q J Med 1992; 85:813.</a></li><li><a class="nounderline abstract_t">Manabe YC, Clark DP, Moore RD, et al. Cryptosporidiosis in patients with AIDS: correlates of disease and survival. Clin Infect Dis 1998; 27:536.</a></li><li><a class="nounderline abstract_t">McGowan I, Hawkins AS, Weller IV. The natural history of cryptosporidial diarrhoea in HIV-infected patients. AIDS 1993; 7:349.</a></li><li><a class="nounderline abstract_t">Connolly GM, Dryden MS, Shanson DC, Gazzard BG. Cryptosporidial diarrhoea in AIDS and its treatment. Gut 1988; 29:593.</a></li><li><a class="nounderline abstract_t">Abubakar I, Aliyu SH, Arumugam C, et al. Prevention and treatment of cryptosporidiosis in immunocompromised patients. Cochrane Database Syst Rev 2007; :CD004932.</a></li><li><a class="nounderline abstract_t">Fox LM, Saravolatz LD. Nitazoxanide: a new thiazolide antiparasitic agent. Clin Infect Dis 2005; 40:1173.</a></li><li><a class="nounderline abstract_t">Amadi B, Mwiya M, Musuku J, et al. Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial. Lancet 2002; 360:1375.</a></li><li><a class="nounderline abstract_t">Rossignol JF, Ayoub A, Ayers MS. Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide. J Infect Dis 2001; 184:103.</a></li><li><a class="nounderline abstract_t">Smith HV, Corcoran GD. New drugs and treatment for cryptosporidiosis. Curr Opin Infect Dis 2004; 17:557.</a></li><li><a class="nounderline abstract_t">Rossignol JF, Kabil SM, el-Gohary Y, Younis AM. Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species. Clin Gastroenterol Hepatol 2006; 4:320.</a></li><li><a class="nounderline abstract_t">Smith NH, Cron S, Valdez LM, et al. Combination drug therapy for cryptosporidiosis in AIDS. J Infect Dis 1998; 178:900.</a></li><li><a class="nounderline abstract_t">Legrand F, Grenouillet F, Larosa F, et al. Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study. Bone Marrow Transplant 2011; 46:858.</a></li><li><a class="nounderline abstract_t">Hong DK, Wong CJ, Gutierrez K. Severe cryptosporidiosis in a seven-year-old renal transplant recipient: case report and review of the literature. Pediatr Transplant 2007; 11:94.</a></li><li><a class="nounderline abstract_t">Palmieri F, Cicalini S, Froio N, et al. Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin. Int J STD AIDS 2005; 16:515.</a></li><li><a class="nounderline abstract_t">Priyamvada PS, Parameswaran S, Morkhandikar S, Shankar V. Successful eradication of cryptosporidium in kidney transplant recipients – Two case reports. Indian Journal of Transplantation 2014.</a></li><li><a class="nounderline abstract_t">Rossignol JF. Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients. Aliment Pharmacol Ther 2006; 24:887.</a></li><li><a class="nounderline abstract_t">Rossignol JF, Hidalgo H, Feregrino M, et al. A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico. Trans R Soc Trop Med Hyg 1998; 92:663.</a></li><li><a class="nounderline abstract_t">Amadi B, Mwiya M, Sianongo S, et al. High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial. BMC Infect Dis 2009; 9:195.</a></li><li><a class="nounderline abstract_t">White AC Jr, Chappell CL, Hayat CS, et al. Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial. J Infect Dis 1994; 170:419.</a></li><li><a class="nounderline abstract_t">Hewitt RG, Yiannoutsos CT, Higgs ES, et al. Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group. Clin Infect Dis 2000; 31:1084.</a></li><li><a class="nounderline abstract_t">Holmberg SD, Moorman AC, Von Bargen JC, et al. Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators. JAMA 1998; 279:384.</a></li><li><a class="nounderline abstract_t">Cabada MM, White AC Jr. Treatment of cryptosporidiosis: do we know what we think we know? Curr Opin Infect Dis 2010; 23:494.</a></li><li><a class="nounderline abstract_t">Fichtenbaum CJ, Zackin R, Feinberg J, et al. Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection. AIDS 2000; 14:2889.</a></li><li><a class="nounderline abstract_t">Giacometti A, Cirioni O, Barchiesi F, et al. Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture. J Antimicrob Chemother 2000; 45:453.</a></li><li><a class="nounderline abstract_t">Gathe JC Jr, Mayberry C, Clemmons J, Nemecek J. Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS. J Acquir Immune Defic Syndr 2008; 48:363.</a></li><li><a class="nounderline abstract_t">Amenta M, Dalle Nogare ER, Colomba C, et al. Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections. J Chemother 1999; 11:391.</a></li><li><a class="nounderline abstract_t">Hicks P, Zwiener RJ, Squires J, Savell V. Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus. J Pediatr 1996; 129:297.</a></li><li><a class="nounderline abstract_t">Blanshard C, Shanson DC, Gazzard BG. Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis. Int J STD AIDS 1997; 8:124.</a></li><li><a class="nounderline abstract_t">Hoepelman AI. Current therapeutic approaches to cryptosporidiosis in immunocompromised patients. J Antimicrob Chemother 1996; 37:871.</a></li><li><a class="nounderline abstract_t">Griffiths JK. Treatment for AIDS-associated cryptosporidiosis. J Infect Dis 1998; 178:915.</a></li><li><a class="nounderline abstract_t">Iroh Tam P, Arnold SLM, Barrett LK, et al. Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial. Clin Infect Dis 2021; 73:183.</a></li><li><a class="nounderline abstract_t">Zardi EM, Picardi A, Afeltra A. Treatment of cryptosporidiosis in immunocompromised hosts. Chemotherapy 2005; 51:193.</a></li><li><a class="nounderline abstract_t">Bhadauria D, Goel A, Kaul A, et al. Cryptosporidium infection after renal transplantation in an endemic area. Transpl Infect Dis 2015; 17:48.</a></li><li><a class="nounderline abstract_t">Krause I, Amir J, Cleper R, et al. Cryptosporidiosis in children following solid organ transplantation. Pediatr Infect Dis J 2012; 31:1135.</a></li><li><a class="nounderline abstract_t">La Hoz RM, Morris MI, AST Infectious Diseases Community of Practice. Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice. Clin Transplant 2019; 33:e13618.</a></li><li><a class="nounderline abstract_t">Hashmey R, Smith NH, Cron S, et al. Cryptosporidiosis in Houston, Texas. A report of 95 cases. Medicine (Baltimore) 1997; 76:118.</a></li><li><a class="nounderline abstract_t">Lanternier F, Amazzough K, Favennec L, et al. Cryptosporidium spp. Infection in Solid Organ Transplantation: The Nationwide "TRANSCRYPTO" Study. Transplantation 2017; 101:826.</a></li><li><a class="nounderline abstract_t">Hussien SM, Abdella OH, Abu-Hashim AH, et al. Comparative study between the effect of nitazoxanide and paromomycine in treatment of cryptosporidiosis in hospitalized children. J Egypt Soc Parasitol 2013; 43:463.</a></li><li><a class="nounderline abstract_t">Lilja M, Widerström M, Lindh J. Persisting post-infection symptoms 2 years after a large waterborne outbreak of Cryptosporidium hominis in northern Sweden. BMC Res Notes 2018; 11:625.</a></li><li><a class="nounderline abstract_t">Kelly P. Treatment and prevention of cryptosporidiosis: what options are there for a country like Zambia? Parasitology 2011; 138:1488.</a></li><li><a class="nounderline abstract_t">Goodgame RW. Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora. Ann Intern Med 1996; 124:429.</a></li><li><a class="nounderline abstract_t">Checkley W, White AC Jr, Jaganath D, et al. A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium. Lancet Infect Dis 2015; 15:85.</a></li><li><a class="nounderline abstract_t">Mead JR. Prospects for immunotherapy and vaccines against Cryptosporidium. Hum Vaccin Immunother 2014; 10:1505.</a></li></ol></div><div id="topicVersionRevision">Topic 16217 Version 26.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Guidelines for the Prevention and Treatment of Opportunistic Infections in Adults and Adolescents with HIV. Available at: https://clinicalinfo.hiv.gov/en/guidelines/adult-and-adolescent-opportunistic-infection/whats-new-guidelines (Accessed on July 25, 2023).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/26568906" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : Treatment of Cryptosporidium: What We Know, Gaps, and the Way Forward.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9457096" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of HIV-1-associated microsporidiosis and cryptosporidiosis with combination antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11103042" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Eradication of cryptosporidia and microsporidia following successful antiretroviral therapy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10795595" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Effect of antiretroviral therapy on cryptosporidiosis and microsporidiosis in patients infected with human immunodeficiency virus type 1.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1362461" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Cryptosporidiosis in HIV-seropositive patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9770154" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Cryptosporidiosis in patients with AIDS: correlates of disease and survival.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8471197" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : The natural history of cryptosporidial diarrhoea in HIV-infected patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/3294122" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Cryptosporidial diarrhoea in AIDS and its treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17253532" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Prevention and treatment of cryptosporidiosis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15791519" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Nitazoxanide: a new thiazolide antiparasitic agent.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12423984" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Effect of nitazoxanide on morbidity and mortality in Zambian children with cryptosporidiosis: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11398117" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Treatment of diarrhea caused by Cryptosporidium parvum: a prospective randomized, double-blind, placebo-controlled study of Nitazoxanide.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15640710" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : New drugs and treatment for cryptosporidiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16527695" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Effect of nitazoxanide in diarrhea and enteritis caused by Cryptosporidium species.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728569" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Combination drug therapy for cryptosporidiosis in AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20729925" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Diagnosis and treatment of digestive cryptosporidiosis in allogeneic haematopoietic stem cell transplant recipients: a prospective single centre study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17239130" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Severe cryptosporidiosis in a seven-year-old renal transplant recipient: case report and review of the literature.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16004637" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Pulmonary cryptosporidiosis in an AIDS patient: successful treatment with paromomycin plus azithromycin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : Successful eradication of cryptosporidium in kidney transplant recipients–Two case reports</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16918894" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Nitazoxanide in the treatment of acquired immune deficiency syndrome-related cryptosporidiosis: results of the United States compassionate use program in 365 patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10326116" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : A double-'blind' placebo-controlled study of nitazoxanide in the treatment of cryptosporidial diarrhoea in AIDS patients in Mexico.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19954529" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : High dose prolonged treatment with nitazoxanide is not effective for cryptosporidiosis in HIV positive Zambian children: a randomised controlled trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8035029" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Paromomycin for cryptosporidiosis in AIDS: a prospective, double-blind trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11049793" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Paromomycin: no more effective than placebo for treatment of cryptosporidiosis in patients with advanced human immunodeficiency virus infection. AIDS Clinical Trial Group.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9459473" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Possible effectiveness of clarithromycin and rifabutin for cryptosporidiosis chemoprophylaxis in HIV disease. HIV Outpatient Study (HOPS) Investigators.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20689422" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Treatment of cryptosporidiosis: do we know what we think we know?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11153670" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Rifabutin but not clarithromycin prevents cryptosporidiosis in persons with advanced HIV infection.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10747821" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Activity of nitazoxanide alone and in combination with azithromycin and rifabutin against Cryptosporidium parvum in cell culture.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18580340" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Resolution of severe cryptosporidial diarrhea with rifaximin in patients with AIDS.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10632386" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : Intestinal protozoa in HIV-infected patients: effect of rifaximin in Cryptosporidium parvum and Blastocystis hominis infections.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8765631" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Azithromycin therapy for Cryptosporidium parvum infection in four children infected with human immunodeficiency virus.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9061412" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Pilot studies of azithromycin, letrazuril and paromomycin in the treatment of cryptosporidiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8737137" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Current therapeutic approaches to cryptosporidiosis in immunocompromised patients.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9728573" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : Treatment for AIDS-associated cryptosporidiosis.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32277809" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Clofazimine for Treatment of Cryptosporidiosis in Human Immunodeficiency Virus Infected Adults: An Experimental Medicine, Randomized, Double-blind, Placebo-controlled Phase 2a Trial.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16006765" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Treatment of cryptosporidiosis in immunocompromised hosts.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25620388" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Cryptosporidium infection after renal transplantation in an endemic area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/22810017" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Cryptosporidiosis in children following solid organ transplantation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/31145496" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Intestinal parasites including Cryptosporidium, Cyclospora, Giardia, and Microsporidia, Entamoeba histolytica, Strongyloides, Schistosomiasis, and Echinococcus: Guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9100739" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : Cryptosporidiosis in Houston, Texas. A report of 95 cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27681270" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Cryptosporidium spp. Infection in Solid Organ Transplantation: The Nationwide "TRANSCRYPTO" Study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24260825" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Comparative study between the effect of nitazoxanide and paromomycine in treatment of cryptosporidiosis in hospitalized children.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/30165888" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Persisting post-infection symptoms 2 years after a large waterborne outbreak of Cryptosporidium hominis in northern Sweden.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21320387" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Treatment and prevention of cryptosporidiosis: what options are there for a country like Zambia?</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/8554253" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Understanding intestinal spore-forming protozoa: cryptosporidia, microsporidia, isospora, and cyclospora.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/25278220" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidium.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24638018" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Prospects for immunotherapy and vaccines against Cryptosporidium.</p>
</a>
</div>
</div>
</div>
</div>
</section>
</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->
<!-- End Footer Area -->
<!-- Back to top -->
<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->
<!-- Prpper JS -->
<!-- Bootstrap Min JS -->
<!-- Classy Nav Min Js -->
<!-- Owl Carousel Min Js -->
<!-- Magnific Popup JS -->
<!-- CounterUp JS -->
<!-- Waypoints JS -->
<!-- Form Validator Min JS -->
<!-- Contact Form Min JS -->
<!-- Main JS -->
<!-- Global site tag (gtag.js) - Google Analytics -->
</body>
</html>
